FIELD: medicine.
SUBSTANCE: invention relates to methods of treating breast cancer comprising administering aqueous suspensions containing solubilized fulvestrant, non-solubilized fulvestrant particles having one or more of LD Dv(10) from about 1.5 to about 2.1 µm, LD Dv(50) from about 5.5 to about 9.0 µm and LD Dv(90) from about 15 to about 35 µm, while aqueous suspensions additionally include a surfactant, polyvinylpyrrolidone, sugar alcohol and a water-soluble excipient. The water soluble excipient may be aryl-C1-6-alk-OH, C1-6-alkyl-OH, buffer salt, polysorbate, polyalkylene glycol, C1-12-alkylene glycol, phosphatidylcholine, or a combination thereof.
EFFECT: obtaining fulvestrant compositions.
34 cl, 4 ex, 16 tbl, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FULVESTRANT COMPOSITIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2775225C2 |
| METHOD FOR INTRODUCTION OF PALIPERIDONE PALMITATE SUSPENSION FOR INJECTIONS WITH PROLONGED RELEASE | 2018 |
|
RU2777552C2 |
| FORMULATIONS OF INTRAVENOUS SOLUTIONS OF POSACONAZOLE STABILISED BY SUBSTITUTED BETA-CYCLODEXTRINE | 2011 |
|
RU2575768C2 |
| METHOD FOR TREATMENT OF PROSTATE GLAND DISEASES BASED ON LOCAL DELIVERY OF ACTIVE MATERIALS | 2006 |
|
RU2404747C2 |
| COMPOSITIONS OF GRAPIPRANTE AND METHODS OF THEIR USE | 2015 |
|
RU2811411C2 |
| COMPOSITIONS OF GRAPIPRANT AND METHODS FOR USING SAME | 2015 |
|
RU2679631C2 |
| CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND SOLID FORMS FOR TREATING CONGENITAL ADRENAL HYPERPLASIA | 2019 |
|
RU2824490C2 |
| PHARMACEUTICAL COMPOSITION AND METHODS FOR USE | 2017 |
|
RU2719450C1 |
| PROLONGED SLOW RELEASE PHARMACEUTICAL COMPOSITION CONTAINING WATER SUSPENSION OF BISPHOSPHONATE | 2007 |
|
RU2453316C2 |
| COMPLEMENT ACTIVITY MODULATORS | 2016 |
|
RU2733720C2 |
